These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36802176)

  • 1. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
    United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.
    Hanzel J; Jansen JM; Ter Steege RWF; Gecse KB; D'Haens GR
    Inflamm Bowel Dis; 2022 Mar; 28(4):495-501. PubMed ID: 34013959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Pranzo G; Rodinò S; Scarcelli A; Zampaletta C; Brozzi L; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Fiorella S; Iannelli C; Larussa T; Le Grazie M; Luppino I; Meucci C; FaggianI R; Pagnini C; Perazzo P; Rodriguez-Castro KI; Sacco R; Sebkova L; Serio M; De Monti A; Picchio M; Napolitano D; Schiavoni E; Turchini L; Scaldaferri F; Pugliese D; Guidi L; Laterza L; Privitera G; Pizzoferrato M; Lopetuso LR; Armuzzi A; Elisei W; Maconi G; Papa A
    Expert Opin Biol Ther; 2022 Feb; 22(2):313-320. PubMed ID: 34904510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
    Macaluso FS; Fries W; Viola A; Centritto A; Cappello M; Giuffrida E; Privitera AC; Piccillo G; Magnano A; Vinci E; Vassallo R; Trovatello A; Belluardo N; Giangreco E; Camilleri S; Garufi S; Bertolami C; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Orlando A
    Inflamm Bowel Dis; 2021 Jan; 27(2):182-189. PubMed ID: 32083291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F
    Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
    Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
    Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
    Lovero R; Losurdo G; La Fortezza RF; Terracciano F; Biscaglia G; Martino G; Nardella M; Di Leo A; Principi M; Andriulli A; Bossa F
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):201-207. PubMed ID: 33369956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
    Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ
    Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
    Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.
    Pugliese D; Guidi L; Privitera G; Bertani L; Tolusso B; Papparella LG; Maltinti S; Di Mario C; Onali S; Ceccarelli L; Rapaccini GL; Scaldaferri F; Gremese E; Gasbarrini A; Costa F; Armuzzi A
    Expert Opin Biol Ther; 2021 Jan; 21(1):97-104. PubMed ID: 33074723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Clinical Outcomes After Switching from Remicade
    Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
    Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.